Both MARCH1 and MARCH2 were found to be able to differentially inhibit infection by pseudoviruses harboring RABV-G, LCMV-GP, CHIKV and RRV envelope glycoproteins but not the S proteins of SARS-CoV and SARS-CoV-2 although MARCH8 showed the highest inhibitory activity against all viral envelope glycoproteins tested (Fig. S5). This evidence concerns the gene MARCHF8 and infection.